少突胶质细胞瘤的遗传学与影像学
Genetics and imaging of oligodendroglial tumors.
作者信息
Ellenbogen Jonathan R, Walker Carol, Jenkinson Michael D
机构信息
Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Lower Lane, Liverpool, L9 7LJ, UK.
Institute of Translational Medicine, University of Liverpool, Clinical Science Centre, Liverpool, L9 7LJ, UK.
出版信息
CNS Oncol. 2015;4(5):307-15. doi: 10.2217/cns.15.37. Epub 2015 Oct 19.
Abstract
Oligodendroglial tumors are chemosensitive with a favorable prognosis compared with other histological subtypes. The genetic hallmark of co-deletion of 1p and 19q determines both treatment response and prognosis. While this test now forms part of routine histopathology diagnosis in many laboratories, alternative noninvasive imaging biomarkers of tumor genotype remain an attractive proposition. This review will focus on imaging biomarkers of molecular genetics in oligodendroglial tumors.
摘要
与其他组织学亚型相比，少突胶质细胞瘤对化疗敏感，预后良好。1p和19q共缺失的基因特征决定了治疗反应和预后。虽然现在这项检测在许多实验室已成为常规组织病理学诊断的一部分，但肿瘤基因型的替代性非侵入性成像生物标志物仍然是一个有吸引力的提议。本综述将聚焦于少突胶质细胞瘤分子遗传学的成像生物标志物。
相似文献
1
Genetics and imaging of oligodendroglial tumors.
CNS Oncol. 2015;4(5):307-15. doi: 10.2217/cns.15.37. Epub 2015 Oct 19.
2
Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
Clin Cancer Res. 2002 Jan;8(1):196-201.
3
4
Alpha-internexin and altered CIC expression as a supportive diagnostic marker for oligodendroglial tumors with the 1p/19q co-deletion.
Brain Tumor Pathol. 2014 Oct;31(4):257-64. doi: 10.1007/s10014-013-0168-7. Epub 2013 Nov 7.
5
Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features.
Brain. 2006 Jul;129(Pt 7):1884-91. doi: 10.1093/brain/awl108. Epub 2006 May 2.
6
Fluorescent in situ hybridization on isolated tumor cell nuclei: a sensitive method for 1p and 19q deletion analysis in paraffin-embedded oligodendroglial tumor specimens.
Mod Pathol. 2003 Jul;16(7):708-15. doi: 10.1097/01.MP.0000076981.90281.BF.
7
Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
Clin Cancer Res. 2007 Dec 1;13(23):6933-7. doi: 10.1158/1078-0432.CCR-07-0573.
8
MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes.
Neurology. 2005 Jun 28;64(12):2085-9. doi: 10.1212/01.WNL.0000165998.73779.D9.
9
MR imaging characteristics of oligodendroglial tumors with assessment of 1p/19q deletion status.
Acta Neurochir (Wien). 2010 Nov;152(11):1827-34. doi: 10.1007/s00701-010-0743-1. Epub 2010 Aug 15.
10
Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
Clin Neuropathol. 2006 Jan-Feb;25(1):18-24.
引用本文的文献
1
5-ALA in Suspected Low-Grade Gliomas: Current Role, Limitations, and New Approaches.
Front Oncol. 2021 Jul 30;11:699301. doi: 10.3389/fonc.2021.699301. eCollection 2021.
2
Differential diagnosis of oligodendroglial and astrocytic tumors using imaging results: the added value of perfusion MR imaging.
Neuroradiology. 2017 Jul;59(7):665-675. doi: 10.1007/s00234-017-1851-x. Epub 2017 May 26.
本文引用的文献
1
Differentiation between oligodendroglioma genotypes using dynamic susceptibility contrast perfusion-weighted imaging and proton MR spectroscopy.
AJNR Am J Neuroradiol. 2013 Aug;34(8):1542-9. doi: 10.3174/ajnr.A3384. Epub 2013 Jan 31.
2
Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis?
AJNR Am J Neuroradiol. 2013 Jul;34(7):1326-33. doi: 10.3174/ajnr.A3352. Epub 2012 Dec 6.
3
11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors.
AJNR Am J Neuroradiol. 2013 Jan;34(1):85-91. doi: 10.3174/ajnr.A3173. Epub 2012 Jul 5.
4
Biology, genetics and imaging of glial cell tumours.
Br J Radiol. 2011 Dec;84 Spec No 2(Spec Iss 2):S90-106. doi: 10.1259/bjr/23430927.
5
Detection of "oncometabolite" 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma.
J Mol Med (Berl). 2012 Oct;90(10):1161-1171. doi: 10.1007/s00109-012-0888-x. Epub 2012 Mar 17.
6
Magnetic resonance imaging volumetric assessment of the extent of contrast enhancement and resection in oligodendroglial tumors.
J Neurosurg. 2012 Jun;116(6):1172-81. doi: 10.3171/2012.2.JNS102032. Epub 2012 Mar 16.
7
2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas.
Nat Med. 2012 Jan 26;18(4):624-9. doi: 10.1038/nm.2682.
8
Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.
Sci Transl Med. 2012 Jan 11;4(116):116ra5. doi: 10.1126/scitranslmed.3002796.
9
Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.
Sci Transl Med. 2012 Jan 11;4(116):116ra4. doi: 10.1126/scitranslmed.3002693.
10
Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.
J Neurooncol. 2012 Mar;107(1):197-205. doi: 10.1007/s11060-011-0737-8. Epub 2011 Oct 21.
Zotero 插件